Key result
AIM2 deficiency attenuates post-ischemia-reperfusion cardiac dysfunction and pyroptosis in aged mice.
Why the study?
Although evidence suggests an association between AIM2 inflammasome activation and cardiovascular diseases, its contribution to age-related cardiac complications and the cardiac response to ischemia-reperfusion injury remains unknown.
Does AIM2 deficiency or pharmacological inhibition attenuate post-ischemia-reperfusion cardiac dysfunction and pro-inflammatory signaling in aged mice and senescent human cardiomyocytes?
Does AIM2 deficiency or pharmacological inhibition attenuate post-ischemia-reperfusion cardiac dysfunction and pro-inflammatory signaling in aged mice and senescent human cardiomyocytes?
Answers are grounded in this paper and cite their sources.
Age-dependent induction of the AIM2 inflammasome primes a pro-inflammatory and pro-pyroptotic cardiac microenvironment that exacerbates ischemia-reperfusion injury in aged mouse hearts, identifying AIM2 as a potential therapeutic target in cardiac aging.
Cardiac aging increases susceptibility to cardiovascular diseases, particularly myocardial infarction. Although evidence suggest association between activation of the AIM2 inflammasome and cardiovascular diseases, its contribution to age-related cardiac complications remains unknown. We investigated the role of the AIM2 inflammasome and the cardiac response to ischemia–reperfusion (I/R) injury in aged mice. Male wildtype (C57BL/6) and AIM2-deficient (AIM2-/-) mice were subjected to natural aging (21 months), using 3-month-old mice as controls, and human cardiomyocytes (AC16) were stressed by hydrogen peroxide to mimic senescent. AIM2 expression was upregulated in the aged myocardium and senescent AC16 cells, coinciding with increased levels of cleaved caspase-1 (p20), IL-1β, and IL-18. Functional assays in Langendorff-perfused hearts revealed that AIM2 deficiency significantly attenuated post-I/R dysfunction in aged mice, restoring left ventricular developed pressure (LVDP) and pressure derivatives (+dP/dTmax and −dP/dTmin) toward pre-ischemic levels. While AIM2 absence did not alter age-associated hypertrophy, fibrosis, longevity, or senescence markers (p53 and p21), it reduced the baseline pro-inflammatory and pro-pyroptotic profile of the aged heart (IL-1β, IL-18, GSDMD-N, and ASC speck). In vitro, AIM2 activation using Poly(dA:dT) elevated IL-1β, GSDMD-N, ASC speck, and cell death in senescent cells, whereas pharmacological inhibition with A151 prevented these effects. Concurrently, age-dependent AIM2 upregulation was confirmed in human cardiac datasets. Together, these findings suggest that age-dependent AIM2 induction primes a pro-inflammatory cardiac microenvironment, exacerbating post-I/R injury and highlighting this pathway for future investigation in the context of cardiac aging.
No takes yet. Share an insight, caveat, or question.
Senger et al. (2026) studied Cardiac aging and ischemia-reperfusion (I/R) injury. AIM2 deficiency (AIM2-/-) and pharmacological AIM2 inhibition (A151) / activation (Poly(dA:dT)) vs. Wildtype (C57BL/6) aged and 3-month-old control mice was evaluated on Post-ischemia-reperfusion cardiac dysfunction (LVDP, +dP/dTmax, and -dP/dTmin) and pro-inflammatory/pyroptotic markers. AIM2 deficiency attenuated post-ischemia-reperfusion cardiac dysfunction in 21-month-old mice, restoring LVDP, +dP/dTmax, and -dP/dTmin toward pre-ischemic levels while reducing IL-1β, IL-18, and GSDMD-N.
Synapse has enriched 10 related papers. Consider them for comparative context: